MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Estimated Relative Effectiveness and Public Health Impact of Cell‐Based Versus Egg‐Based Influenza Vaccines During the 2022–2023 Season in the United States
Estimated Relative Effectiveness and Public Health Impact of Cell‐Based Versus Egg‐Based Influenza Vaccines During the 2022–2023 Season in the United States
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Estimated Relative Effectiveness and Public Health Impact of Cell‐Based Versus Egg‐Based Influenza Vaccines During the 2022–2023 Season in the United States
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Estimated Relative Effectiveness and Public Health Impact of Cell‐Based Versus Egg‐Based Influenza Vaccines During the 2022–2023 Season in the United States
Estimated Relative Effectiveness and Public Health Impact of Cell‐Based Versus Egg‐Based Influenza Vaccines During the 2022–2023 Season in the United States

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Estimated Relative Effectiveness and Public Health Impact of Cell‐Based Versus Egg‐Based Influenza Vaccines During the 2022–2023 Season in the United States
Estimated Relative Effectiveness and Public Health Impact of Cell‐Based Versus Egg‐Based Influenza Vaccines During the 2022–2023 Season in the United States
Journal Article

Estimated Relative Effectiveness and Public Health Impact of Cell‐Based Versus Egg‐Based Influenza Vaccines During the 2022–2023 Season in the United States

2025
Request Book From Autostore and Choose the Collection Method
Overview
Egg adaptation can reduce the effectiveness of egg-based influenza vaccines. Previous studies have demonstrated improved effectiveness of cell versus egg-based quadrivalent influenza vaccines (QIVc and QIVe, respectively) during the 2017-2020 influenza seasons among persons aged ≥ 4 years. Here we evaluate the relative vaccine effectiveness (rVE) of QIVc versus QIVe in preventing test-confirmed influenza among persons aged 6 months to 64 years during the US 2022-2023 influenza season, along with the potential impact on influenza burden averted. A retrospective test-negative design was applied to linked electronic health records and claims data from QIVc or QIVe recipients who were tested for influenza in routine outpatient care within 7 days of an acute respiratory or febrile illness. rVE was estimated by comparing the odds of testing positive among QIVc versus QIVe recipients, adjusted using doubly robust methodology. The influenza burden additionally averted by vaccination with QIVc versus QIVe was estimated using a published model. Of 43,086 patients included, 18.6% received QIVc and 81.4% received QIVe. The rVE of QIVc versus QIVe was 7.7% (95% CI, 0.9%-13.9%). Use of QIVc instead of QIVe during the 2022-23 influenza season would have prevented an additional 636,209 symptomatic cases of influenza, 314,130 outpatient visits, and 3759 hospitalizations. QIVc was superior to QIVe in the prevention of test-confirmed influenza among persons aged 6 months to 64 years during the US 2022-2023 influenza season. The rVE of 7.7% would translate to a substantially reduced influenza burden if QIVc were used over QIVe.